The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line
treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia.
Randomized,Open Label,Control